Achieving Treatment Success for Patients with Heart Failure Complicated by Hyponatremia
Date of release: October 15, 2012
Expiration date: October 14, 2014
Total possible credits: 1.5 AMA PRA Cat 1
Fee: $0.00
Hyponatremia is very difficult to treat in patients with heart failure, and improved treatment strategies represent an urgent clinical need. Recently, vasopressin has emerged as a therapeutic target in the management of hyponatremia. Vasopressin is a central modulator in hyponatremia, underscoring the importance of antagonizing vasopressin at its receptors in patients with hyponatremia and underlying heart failure. Guidelines for the treatment of hyponatremia have been published by several professional associations. The varying recommendations and emerging data on treatment options create challenges for practitioners caring for patients with hyponatremia. Recognizing the possible consequences of unmanaged hyponatremia in heart failure patients and implementing appropriate treatment strategies are critical steps toward improving outcomes in patients with hyponatremia.
The Foundation for Care Management (FCM) and CME-University.
This activity is supported by an educational grant from Otsuka America Pharmaceuticals, Inc.
Effective Management of Asthma By Primary Care Provider
Date of release: January 1, 2013
Expiration date: December 31, 2013
Total possible credits: 1.0 AMA PRA Cat 1
Fee: $0.00
This program will discuss the pathophysiology of asthma and associated small airway inflammation, describe the relevance of small airway inflammation and implications for effective pharmacologic therapy, and review the current recommendations on the use of spirometry for the treatment of patients with asthma.
The Foundation for Care Management (FCM), Not One More Life, and CME-University.
Funded by an independent educational grant from TEVA Pharmaceuticals USA
Hyponatremia: Improving Patient Quality of Life & Outcomes
Date of release: January 15, 2013
Expiration date: January4 1, 2014
Total possible credits: 1.0 AMA PRA Cat 1
Fee: $0.00
Purpose: To enable the endocrinologist and other healthcare professionals to improve hyponatremia patient quality of life and outcomes.
Jointly sponsored by the California Chapter of the American College of Cardiology (CAACC), CME-University, and AKH Inc.
This continuing medical education activity is supported through an educational grant from Otsuka America Pharmaceutical, Inc.
Update On Antiplatelet Therapy in Acute Coronary Syndromes
Date of release: February 1, 2013
Expiration date: January 31, 2014
Total possible credits: 1.0 AMA PRA Cat 1
Fee: $0.00
Acute coronary syndrome (ACS) is a significant contributor to morbidity, mortality and adverse outcomes for patient’s worldwide. In the United States, ACS is responsible for more than 1.5 million hospitalizations and more than 6 million emergency department visits each year. It has been estimated that the total health care costs related to ACS exceed $300 million within the first year following initial patient presentation. The standard of care for the management of ACS is re-establishing coronary circulation through invasive management (i.e. percutaneous coronary intervention [PCI] or coronary artery bypass grafting [CABG]) or through medical management. Recently the ST-Elevation myocardial infarction (STEMI), unstable angina/non-ST-Elevation myocardial infarction (UA/NSTEMI), and PCI guidelines have been updated. These updates recommend treatment for preventing further thrombotic events. Antithrombotic agents are a vital part of these medical and interventional strategies. In addition, new data are emerging on the optimal combinations of antithrombotic treatments, their timing, and appropriate targeted subgroups. This program will review the new guidelines, recent data on the use of antithrombotic therapy, and strategies for improving outcomes in patients with ACS
The Foundation for Care Management (FCM) and CME-University.
This continuing medical education activity is funded by an independent educational grant from Daiichi Sankyo, Inc. and Lilly USA, LLC
Optimal Conditioning Regimens for Autologous Hematopoietic Stem Cell Transplantation and the Role of Pharmacokinetic-Directed Therapy
Expiration date: April 1, 2011
Total possible credits: Credit No Longer Available
Fee: $0.00
This continuing education activity, targeting oncology pharmacists, physicians, and associated hematology oncology practitioners, and administrators specializing in hematology/oncology practice, will provide an overview of Optimal Conditioning Regimens for Autologous Hematopoietic Stem Cell Transplantation and the Role of Pharmacokinetic-Directed Therapy.
Compared with traditional myeloablative approaches, RIC is most commonly performed in adult patients who are older and have more comorbidities. The greatest potential benefit appears to be in older patients with AML in first remission and in those with MDS, yet this still awaits confirmation in prospective trials. Several combination RIC regimens with and without total body irradiation appear effective, and to date there is no way to clearly discern which is best for a particular patient. Despite a recent surge in early-phase data, significant questions remain regarding the most appropriate clinical situations to apply reduced intensity conditioning and allogeneic HCT in patients. Although RIC regimens are associated with lower rates of severe toxicity and non-relapse mortality, the issues of infection, GVHD, and relapse of primary disease remain important obstacles to achieving optimal patient outcomes.
Jointly sponsored by the University of Massachusetts Medical School, Massachusetts College of Pharmacy and Health Sciences and CME-University.
This continuing education activity was supported through an educational grant from Otsuka America Pharmaceuticals, Inc.
Anemia & Blood Transfusion in Orthopedic Surgery
Date Expired: April 2011
Total possible credits: Credit No Longer Available
Fee: $0.00
Anemia is common in surgical patients. Many orthopedic procedures are performed in an elderly patient population, where anemia is even more prevalent. Orthopedic procedures, such as spine surgery and total hip arthroplasty, also involve significant blood loss, which further increases the risk of anemia. The World Health Organization defines anemia as hemoglobin (Hb) concentrations < 12 g/dL in women and < 13 g/dL in men. Significantly lower levels are, however, frequently seen in patients during the perioperative period. The prevalence of anemia is highly variable, depending on the patient population, but may be as high as 40% in older patients.1 Understanding the physiological and clinical implications of anemia is critical for the perioperative management of surgical patients. Furthermore, anemia has a very significant prognostic value because it is associated with important outcomes.
Jointly sponsored by AKH Inc., CME-University and MedEd Global Solutions.
This continuing education activity was supported through an educational grant from Centocor Ortho Biotech Service, LLC.
Dyslipidemia: A Case-Based Approach to Screening and Management
Date Expired: January 2011
Total possible credits: Credit No Longer Available
Fee: $0.00
Family Physicians (FPs) are familiar with the barriers to effective screening and management of lipid abnormalities, and generally familiar with clinical practice guidelines to improve cardiovascular outcomes using a combination of lifestyle modification and pharmacotherapy. However, evidence for solutions to these barriers, including better patient adherence, and better targeting of at-risk patients, are needed to help FPs improve their practice performance for lipid management. Such evidence will help FPs to identify and treat patients at higher risk and to stratify management accordingly. Research information is currently emerging on ethnic and gender disparities in lipid risk factors, screening and management as well as the varying profiles of different statins.
Jointly sponsored by CAFP and CME-University.
This continuing education activity was supported through an educational grant from AstraZeneca
Emerging Options in Reduced-Intensity Conditioning for Stem Cell Transplantation: Who, How & Why
Date Expired: March 2011
Total possible credits: Credit No Longer Available
Fee: $0.00
This program was presented preceding the 51st ASH Annual Meeting, Friday, December 4, 2009, New Orleans, LA. This program consists of summaries of selected faculty presentations, including graphics that were employed. Credit for your participation in this program is no longer available.
Jointly sponsored by The Medical College of Wisconsin (MCW) and CME-University.
This continuing education activity was supported through an educational grant from Otsuka America Pharmaceuticals, Inc.
Addressing Asthma Disparities in Inner City and Minority Populations
Date Expired: March 2013
Total possible credits: Credit No Longer Available
Fee: $0.00
Despite 3 iterations of the NAEPP Guidelines for the Diagnosis and Management of Asthma, disparities in the prevalence, morbidity and mortality of asthma remain alarmingly persistent among certain populations. Healthcare providers must be aware of these disparities in the populations they serve. Moreover, providers must understand current insights into potential causes of these disparities and the related implications for effective provider, patient and community based education and management to reduce and ultimately eliminate these disparities.
Jointly sponsored by AKH Inc., The CHEST Foundation, Not One More Life, Inc., and CME-University.
This activity is provided through an educational grant from TEVA Pharmaceuticals.